BFRI — Biofrontera Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1858685 ·
Last close
$0.80
Market Cap
$10.18M
52W High
$1.19
52W Low
$0.73
ADV30
223,343
Next earnings
2026-08-12
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 10,084,000 7,968,000 -3,928,000 -4,752,000 24,787,000 6,317,000 18,717,000
Dec 2025 17,100,000 14,091,000 4,559,000 5,640,000 28,564,000 6,392,000 18,084,000
Sep 2025 6,988,000 4,943,000 -6,278,000 -6,649,000 15,415,000 3,417,000 17,996,000
Jun 2025 9,030,000 6,388,000 -5,079,000 -5,324,000 20,142,000 7,239,000 24,810,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,361,000
Investing CF
$2,998,000
Financing CF
$10,850,000
CapEx
$-5,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.18
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-127,945,000
Inventory
$1,426,000
Receivables
$8,509,000
ST Investments
$9,000
EBIT TTM
$-9,702,000
Pretax Income TTM
$-10,510,000
Interest Exp TTM
$299,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$43,201,000
EBITDA
$-10,565,000
Free Cash Flow
$1,477,000
Enterprise Value
$10,829,947
Total Cash
$6,326,000
Total Debt
$7,724,000
Shares Out
12,803,344
Trailing EPS
$-0.98
Book Value
$0.52
ROE
-339.0%
ROA
-32.4%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 41,705,000 -11,348,000 -10,536,000 28,564,000 18,084,000 -13,361,000
Dec 2024 37,321,000 -17,210,000 -17,759,000 22,101,000 17,668,000 -10,270,000
Dec 2023 34,071,000 -22,577,000 -20,131,000 27,932,000 23,139,000 -24,895,000
Dec 2022 28,674,000 -22,381,000 -640,000 50,884,000 27,006,000 -16,199,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.32

Peers — same industry

TickerNameMarket CapLastDaily %
PBM PSYENCE BIOMEDICAL LTD. $10.30M $4.49
JUNS JUPITER NEUROSCIENCES, INC. $9.99M $0.23
LABT Lakewood-Amedex Biotherapeutics Inc. $9.98M $0.71
BOLT Bolt Biotherapeutics, Inc. $9.86M $5.13
QNRX Quoin Pharmaceuticals, Ltd. $9.72M $4.84

News headlines (Yahoo Finance, 1h cache)

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-21 13:15 · Yahoo
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
2026-05-19 13:34 · Yahoo
Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
2026-05-14 23:04 · Yahoo
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 13:25 · Yahoo
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
2026-05-14 11:30 · Yahoo
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
2026-05-13 13:00 · Yahoo
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-13 12:35 · Yahoo
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
2026-05-08 20:00 · Yahoo
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
2026-05-07 12:50 · Yahoo
Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
2026-03-21 01:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.